Morphosys (DE:MOR) has released an update.
MorphoSys AG shareholders have given the green light for a ‘merger squeeze-out’, allowing Novartis BidCo Germany AG to acquire remaining minority stakes at €68 per share. The decision was made during a virtual Annual General Meeting with broad shareholder participation. MorphoSys, a biopharmaceutical company focused on cancer treatments, continues to grow as part of the global healthcare landscape.
For further insights into DE:MOR stock, check out TipRanks’ Stock Analysis page.
